Emily Field
Stock Analyst at Barclays
(3.18)
# 2,551
Out of 5,060 analysts
723
Total ratings
46%
Success rate
2%
Average return
Main Sectors:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $59.75 | +25.52% | 9 | Oct 13, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,400 | $1,257.03 | +11.37% | 33 | Oct 12, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $168 → $150 | $145.95 | +2.77% | 14 | Oct 12, 2026 | |
| AMGN Amgen | Reiterated: Hold | $380 | $432.49 | -12.14% | 9 | Sep 17, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $110 | $61.95 | +77.56% | 9 | Aug 26, 2026 | |
| GILD Gilead Sciences | Reiterated: Hold | $145 | $156.19 | -7.16% | 5 | Aug 13, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 | $29.58 | -15.48% | 6 | Aug 13, 2026 | |
| BIIB Biogen | Reiterated: Hold | $200 | $232.65 | -14.03% | 7 | Aug 12, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $300 | $285.42 | +5.11% | 11 | Aug 11, 2026 | |
| GSK GSK plc | Downgraded: Sell | n/a | $49.51 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $150.62 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $57.14 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $40.61 | - | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | CHF 275.00 | CHF 379.20 | n/a | 59 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €115.00 → €105.00 | €71.94 | n/a | 37 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 1,450p | 1,863p | n/a | 126 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 46.50 → CHF 55.00 | CHF 77.18 | n/a | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 14,000p | 12,446p | n/a | 78 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €22.00 | €26.32 | n/a | 32 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | CHF 90.00 | CHF 124.70 | n/a | 44 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | €25.00 | €44.46 | n/a | 59 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 2,000p | 1,662p | n/a | 61 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €195.00 | €144.30 | n/a | 74 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €8.00 → €9.00 | €10.18 | n/a | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | €75.00 | €149.00 | n/a | 22 | Nov 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $140 → $125 | $29.96 | n/a | 7 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52.30 | $22.28 | n/a | 1 | Aug 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $0.000001 | n/a | 1 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $7.64 | n/a | 2 | Jun 1, 2018 |
Bristol-Myers Squibb Company
Oct 13, 2026
Reiterated: Buy
Price Target: $75
Current: $59.75
Upside: +25.52%
Eli Lilly and Company
Oct 12, 2026
Reiterated: Buy
Price Target: $1,400
Current: $1,257.03
Upside: +11.37%
Merck & Co.
Oct 12, 2026
Reiterated: Buy
Price Target: $168 → $150
Current: $145.95
Upside: +2.77%
Amgen
Sep 17, 2026
Reiterated: Hold
Price Target: $380
Current: $432.49
Upside: -12.14%
Cytokinetics
Aug 26, 2026
Reiterated: Buy
Price Target: $110
Current: $61.95
Upside: +77.56%
Gilead Sciences
Aug 13, 2026
Reiterated: Hold
Price Target: $145
Current: $156.19
Upside: -7.16%
Pfizer
Aug 13, 2026
Reiterated: Sell
Price Target: $25
Current: $29.58
Upside: -15.48%
Biogen
Aug 12, 2026
Reiterated: Hold
Price Target: $200
Current: $232.65
Upside: -14.03%
AbbVie
Aug 11, 2026
Reiterated: Buy
Price Target: $300
Current: $285.42
Upside: +5.11%
GSK plc
Jan 6, 2026
Downgraded: Sell
Price Target: n/a
Current: $49.51
Upside: -
Jan 6, 2026
Upgraded: Hold
Price Target: n/a
Current: $150.62
Upside: -
Jan 6, 2026
Upgraded: Buy
Price Target: n/a
Current: $57.14
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $40.61
Upside: -
Sep 24, 2025
Reiterated: Hold
Price Target: CHF 275.00
Current: CHF 379.20
Upside: n/a
Aug 12, 2025
Reiterated: Buy
Price Target: €115.00 → €105.00
Current: €71.94
Upside: n/a
Aug 12, 2025
Reiterated: Hold
Price Target: 1,450p
Current: 1,863p
Upside: n/a
Aug 8, 2025
Reiterated: Buy
Price Target: CHF 46.50 → CHF 55.00
Current: CHF 77.18
Upside: n/a
Jul 30, 2025
Reiterated: Buy
Price Target: 14,000p
Current: 12,446p
Upside: n/a
Jul 29, 2025
Reiterated: Sell
Price Target: €22.00
Current: €26.32
Upside: n/a
Jul 21, 2025
Reiterated: Sell
Price Target: CHF 90.00
Current: CHF 124.70
Upside: n/a
Jun 27, 2025
Reiterated: Hold
Price Target: €25.00
Current: €44.46
Upside: n/a
Apr 25, 2025
Reiterated: Hold
Price Target: 2,000p
Current: 1,662p
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: €195.00
Current: €144.30
Upside: n/a
Nov 21, 2022
Reiterated: Sell
Price Target: €8.00 → €9.00
Current: €10.18
Upside: n/a
Nov 25, 2021
Reiterated: Sell
Price Target: €75.00
Current: €149.00
Upside: n/a
Jan 19, 2021
Reiterated: Hold
Price Target: $140 → $125
Current: $29.96
Upside: n/a
Aug 28, 2020
Reiterated: Hold
Price Target: $52.30
Current: $22.28
Upside: n/a
Apr 25, 2019
Reiterated: Buy
Price Target: $14
Current: $0.000001
Upside: n/a
Jun 1, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $7.64
Upside: n/a